Biotechs Considered but not on FN

GlycoMimetics (GLYC) – In Phase 3 but data not available until 2H of 2022. As of 5/28/21 had cash balance equal to Market Cap ~$120M. (might cover this one in the future)

Savara (SVRA) – Due to start Phase 3 in 2021, but will not have data until 2024. As of 6/3/21 had market cap of $200M with SP around $1.78. Lot more dilution coming to finish the P3 trial.

Selecta Biosciences (SELB) – P3 readout in 2H 2021, but commercial rights are granted to someone else, therefore somewhat limited upside. As of 6/3/21 had market cap of $508M with SP around $4.40. 

Fortress Biotech (FBIO) – Multiple drugs (some in P3), multiple companies and multiple partnerships. To complex to cover on FN. As of 6/5/21 had market cap of $377M with SP around $4.00. 

Akari Therapeutics (AKTX) – Good P3 drug, but just started P3 and readout not until 2024 (I think) – too far out for FN. As of 6/5/21 had market cap of $69M with SP around $1.79. 

Jaguar Health (JAGX) – Already approved drug (Mytesi) is in P3 for a large indication. But patent expires in 2022. Generics will soon arrive on the market. Limited upside. As of 6/5/21 had market cap of $243M with SP around $1.77. 

Novan, Inc. (NOVN) – P3 readout is any day in 2Q. If they don’t hit their endpoint the company will be finished. Good upside if P3 is successful. To close to readout to make a FN page. As of 6/5/21 had market cap of $118M with SP around $7.80. 

BioMx, Inc. (PHGE) – P3 readout on Acne coming up, but company is a wide variety of drugs for different indications. Not ideal from a FN perspective – like companies that are focused and have a deep knowledge of specialized indications. As of 7/4//21 had a MC of $124M with a SP of $5.10.